Chronologie

Répartition des droits

Ayants droit économique déclarés · 22

Une seule déclaration, déposée collectivement : le taux de droits de vote porte sur le groupe entier, pas sur chaque personne.

• Aravis Venture I LP6.3%
• Astellas Venture Capital, LLC6.3%
• Auriga Ventures III6.3%
• Baltisches Haus Limited6.3%
• BioMedInvest II LP6.3%
• A/S Dansk Erhvervsinvestering6.3%
• Entrepreneurs Fund General Partners Limited6.3%
• Evolva Holding SA6.3%
• Mona Lisa Capital SA6.3%
• Novartis Bioventures Ltd6.3%
• Renaisance PME fondation suisse d investissement / Mona Lisa6.3%
• Sunstone Life Science Ventures Fund I K/S6.3%
• Symbion Capital I A/S6.3%
• Wellington Partners Ventures III Life Science Fund L.P6.3%
• Wellington Partners Ventures III Life Science Network Fund L6.3%
• Neil Goldsmith6.3%
• Alexandra SantAna Sørensen6.3%
• Pascal Longchamp6.3%
• Jakob Dynnes Hansen6.3%
• Jutta Heim6.3%
• PM Murali6.3%
• Vaekstfonden6.3%

Détails de l'annonce

Ayant droit économique

Aravis Venture I LP

On December 13, 2010 the members of the group (the Sale Group) have agreed to execute a coordinated sale by way of block trades and sales on the market of the SIX Swiss Exchange Ltd. with regard to 10% of their aggregate holdings as per December 13, 2010 (i.e., with regard to 12,380,977 shares) up to and including May 23, 2011. On May 17, 2011 the Sale Group has agreed to extend the coordinated sale by way of block trades and sales on the market of the SIX Swiss Exchange Ltd with regard to the remaining 8,794,076 shares. This extension is of unlimited nature, i.e. until terminated. The termination of the group will be disclosed. On 30 May 2011, the participants in Danske Innovationsinvestering (DI), one of the members of the Lock-up Group, decided to liquidate the DI fund and distribute the Evolva shares to its shareholders: Vaekstfonden and A/S A/S Dansk Erhvervsinvestering. The purpose of the present disclosure is to show the changed composition of the Sale Group. Additional information can be downloaded from the Evolva website: www.evolva.com/press-investors/investors/disclosure-shareholdings